Clinical and genetic predictors of diabetes drug’s response

References

• ADA. 2019. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 42(Suppl 1):S90–S102.
   PubMedGoogle Scholar
• Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. 2009a. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes. 58(3):745–749.
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. 2009b. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus [Research Support, Non-U.S. Gov't]. Pharmacogenomics J. 9(4):242–247.
   PubMed Web of Science ®Google Scholar
• Berkovic MC, Bilic-Curcic I, Herman Mahecic D, Gradiser M, Grgurevic M, Bozek T. 2017. Long-term effectiveness of liraglutide in association with patients' baseline characteristics in real-life setting in Croatia: an observational, retrospective, multicenter study. Diabetes Ther. 8(6):1297–1308.
   PubMed Web of Science ®Google Scholar
• Bujac S, Del Parigi A, Sugg J, Grandy S, Liptrot T, Karpefors M, Chamberlain C, Boothman AM. 2014. Patient characteristics are not associated with clinically important differential response to dapagliflozin: a staged analysis of phase 3 data. Diabetes Ther. 5(2):471–482.
   PubMed Web of Science ®Google Scholar
• Burton JH, Johnson M, Johnson J, Hsia DS, Greenway FL, Heiman ML. 2015. Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels. J Diabetes Sci Technol. 9(4):808–814.
   PubMedGoogle Scholar
• Cascorbi I, Schwab M. 2016. Epigenetics in drug response. Clin Pharmacol Ther. 99(5):468–470.
   PubMed Web of Science ®Google Scholar
• Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, Portman MA, Chen E, Ferrin TE, Sali A, et al. 2010. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics. 20(11):687–699.
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang R, Jiang F, Wang J, Peng D, Yan J, Wang S, Wang T, Bao Y, Hu C, et al. 2016. Joint effects of diabetic-related genomic loci on the therapeutic efficacy of oral anti-diabetic drugs in Chinese type 2 diabetes patients. Sci Rep. 6:23266.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, et al. 2009. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics. 19(7):497–504.
   PubMed Web of Science ®Google Scholar
• Chen YW, Wang JS, Sheu WH, Lin SY, Lee IT, Song YM, Fu CP, Lee CL. 2017. Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. PLoS One. 12(2):e0171753.
   PubMed Web of Science ®Google Scholar
• Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ, Mefford JA, Hesselson SE, Schlessinger A, Jenkins G, et al. 2011. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther. 90(5):674–684.
   PubMed Web of Science ®Google Scholar
• Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, Brosen K. 2011. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 21(12):837–850.
   PubMed Web of Science ®Google Scholar
• Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, Brosen K. 2015. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c: corrigendum. Pharmacogen Genom. 25(1):48–50.
   Web of Science ®Google Scholar
• Cook MN, Girman CJ, Stein PP, Alexander CM. 2007. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med. 24(4):350–358.
   PubMed Web of Science ®Google Scholar
• [DC] Diabetes Canada Clinical Practice Guidelines. 2018. Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes. 42(Suppl 1):S88–S103.
   PubMedGoogle Scholar
• de Luis DA, Diaz Soto G, Izaola O, Romero E. 2015. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor. J Diabetes Complicat. 29(4):595–598.
   PubMed Web of Science ®Google Scholar
• Del Prato S, Patel S, Crowe S, von Eynatten M. 2016. Efficacy and safety of linagliptin according to patient baseline characteristics: a pooled analysis of three phase 3 trials. Nutr Metab Cardiovasc Dis. 26(10):886–892.
   PubMed Web of Science ®Google Scholar
• den Ouden H, Pellis L, Rutten GE, Geerars-van Vonderen IK, Rubingh CM, van Ommen B, van Erk MJ, Beulens JW. 2016. Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes. Metabolomics. 12(2):27.
   PubMed Web of Science ®Google Scholar
• Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, et al. 2018. Precision medicine in type 2 diabetes: clinical markers of insulin resistance are associated with altered short- and long-term glycemic response to DPP-4 inhibitor therapy. Diabetes Care. 41(4):705–712.
   PubMed Web of Science ®Google Scholar
• Dhawan D, Padh H. 2016. Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics. Diabetes Res Clin Pract. 121:35–40.
   PubMed Web of Science ®Google Scholar
• Duan F, Guo Y, Zhang L, Chen P, Wang X, Liu Z, Hu Y, Chen S, Chen D. 2016. Association of KCNQ1 polymorphisms with gliclazide efficacy in Chinese type 2 diabetic patients. Pharmacogenet Genom. 26(4):178.
   PubMed Web of Science ®Google Scholar
• Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER. 2015. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes. 64(5):1786–1793.
   PubMed Web of Science ®Google Scholar
• Dujic T, Zhou K, Yee SW, van Leeuwen N, de Keyser CE, Javorský M, Goswami S, Zaharenko L, Hougaard Christensen MM, Out M, et al. 2017. Variants in pharmacokinetic transporters and glycemic response to metformin: a metgen meta-analysis. Clin Pharmacol Ther. 101(6):763–772.
   PubMed Web of Science ®Google Scholar
• Duong JK, Kumar SS, Kirkpatrick CM, Greenup LC, Arora M, Lee TC, Timmins P, Graham GG, Furlong TJ, Greenfield JR, et al. 2013. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet. 52(5):373–384.
   PubMed Web of Science ®Google Scholar
• El-Sisi AE, Hegazy SK, Metwally SS, Wafa AM, Dawood NA. 2011. Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in Egyptian patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2(4):155–164.
   PubMedGoogle Scholar
• Enigk U, Breitfeld J, Schleinitz D, Dietrich K, Halbritter J, Fischer-Rosinsky A, Enigk B, Muller I, Spranger J, Pfeiffer A, et al. 2011. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics. 12(8):1119–1126.
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Maiorino MI, Capuano A, Cozzolino D, Petrizzo M, Bellastella G, Giugliano D. 2015. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open. 5(2):e005892.
   PubMed Web of Science ®Google Scholar
• Feng Y, Mao G, Ren X, Xing H, Tang G, Li Q, Li X, Sun L, Yang J, Ma W, et al. 2008. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care. 31(10):1939–1944.
   PubMed Web of Science ®Google Scholar
• Florez JC, Jablonski KA, Taylor A, Mather K, Horton E, White NH, Barrett-Connor E, Knowler WC, Shuldiner AR, Pollin TI, et al. 2012. The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care. 35(9):1864–1867.
   PubMed Web of Science ®Google Scholar
• Fodor A, Cozma A, Karnieli E. 2015. Personalized epigenetic management of diabetes. Per Med. 12(5):497–514.
   PubMed Web of Science ®Google Scholar
• Fodor A, Karnieli E. 2016. Challenges of implementing personalized (precision) medicine: a focus on diabetes. Per Med. 13(5):485–497.
   PubMed Web of Science ®Google Scholar
• Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Krogh Pedersen H, et al. 2015. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 528(7581):262–266.
   PubMed Web of Science ®Google Scholar
• Francke S, Mamidi R, Solanki B, Scheers E, Jadwin A, Favis R, Devineni D. 2015. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol. 55(9):1061–1072.
   PubMed Web of Science ®Google Scholar
• Ghaffari-Cherati M, Mahrooz A, Hashemi-Soteh MB, Hosseyni-Talei SR, Alizadeh A, Nakhaei SM. 2016. Allele frequency and genotype distribution of a common variant in the 3´-untranslated region of the SLC22A3 gene in patients with type 2 diabetes: association with response to metformin. J Res Med Sci. 21:92.
   PubMed Web of Science ®Google Scholar
• Gorgojo-Martinez JJ, Gargallo-Fernandez MA, Brito-Sanfiel M, Lisbona-Catalan A. 2018. Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: the CIBELES project. Int J Clin Pract. 72(3):e13055.
   PubMed Web of Science ®Google Scholar
• Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R, Mefford JA, Wen C, Liang X, Witte J, et al. 2014. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 96(3):370–379.
   PubMed Web of Science ®Google Scholar
• Goswami S, Yee SW, Xu F, Sridhar SB, Mosley JD, Takahashi A, Kubo M, Maeda S, Davis RL, Roden DM, et al. 2016. A longitudinal HbA1c model elucidates genes linked to disease progression on metformin. Clin Pharmacol Ther. 100(5):537–547.
   PubMed Web of Science ®Google Scholar
• Gotthardova I, Javorsky M, Klimcakova L, Kvapil M, Schroner Z, Kozarova M, Malachovska Z, Urgeova A, Zidzik J, Tkac I. 2017. KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors. Diabetes Res Clin Pract. 130:142–147.
   PubMed Web of Science ®Google Scholar
• Grasset E, Puel A, Charpentier J, Collet X, Christensen JE, Terce F, Burcelin R. 2017. A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism. Cell Metab. 25(5):1075–1090 e1075.
   PubMed Web of Science ®Google Scholar
• Gu Y, Wang X, Li J, Zhang Y, Zhong H, Liu R, Zhang D, Feng Q, Xie X, Hong J, et al. 2017. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun. 8(1):1785.
   PubMed Web of Science ®Google Scholar
• Hakooz N, Jarrar YB, Zihlif M, Imraish A, Hamed S, Arafat T. 2017. Effects of the genetic variants of organic cation transporters 1 and 3 on the pharmacokinetics of metformin in Jordanians. Drug Metab Pers Ther. 32(3):157–162.
   PubMedGoogle Scholar
• Han E, Park HS, Kwon O, Choe EY, Wang HJ, Lee YH, Lee SH, Kim CH, Kim LK, Kwak SH, et al. 2016. A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes. Medicine (Baltimore)). 95(44):e5155.
   PubMed Web of Science ®Google Scholar
• Han J, Yu H, Tu Y, Pang J, Liu F, Bao Y, Yang W, Jia W. 2017. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial. Diabet Med. 34(4):490–499.
   PubMed Web of Science ®Google Scholar
• Hoeben E, De Winter W, Neyens M, Devineni D, Vermeulen A, Dunne A. 2015. Population pharmacokinetic modeling of canagliflozin in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet. 55(2):209–223.
   Web of Science ®Google Scholar
• Holstein A, Hahn M, Korner A, Stumvoll M, Kovacs P. 2011. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet. 12:30.
   PubMed Web of Science ®Google Scholar
• Hou W, Zhang D, Lu W, Zheng T, Wan L, Li Q, Bao Y, Liu F, Jia W. 2015. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients. Mol Diagn Ther. 19(1):25–33.
   PubMed Web of Science ®Google Scholar
• [IDF] International Diabetes Federation. 2017. Diabetes Atlas. 8th ed. http://diabetesatlas.org/resources/2017-atlas.html.
   Google Scholar
• Imai K, Tsujimoto T, Goto A, Goto M, Kishimoto M, Yamamoto-Honda R, Noto H, Kajio H, Noda M. 2014. Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes. Diabetol Metab Syndr. 6(1):110.
   PubMedGoogle Scholar
• Ioacara S, Flanagan S, Frohlich-Reiterer E, Goland R, Fica S. 2017. First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment. J Diabetes Investig. 8(5):716–719.
   PubMed Web of Science ®Google Scholar
• Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, Saxena R, Fowler S, Shuldiner AR, Knowler WC, et al. 2010. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes. 59(10):2672–2681.
   PubMed Web of Science ®Google Scholar
• Jamaluddin JL, Huri HZ, Vethakkan SR. 2016. Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. Pharmacogenomics. 17(8):867–881.
   PubMed Web of Science ®Google Scholar
• Javorsky M, Gotthardova I, Klimcakova L, Kvapil M, Zidzik J, Schroner Z, Doubravova P, Gala I, Dravecka I, Tkac I. 2016. A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins. Diabetes Obes Metab. 18(9):941–944.
   PubMed Web of Science ®Google Scholar
• Javorsky M, Klimcakova L, Schroner Z, Zidzik J, Babjakova E, Fabianova M, Kozarova M, Tkacova R, Salagovic J, Tkac I. 2012. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Europ J Int Med. 23(3):245–249.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, ADOPT Study Group, et al. 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 355(23):2427–2443.
   PubMed Web of Science ®Google Scholar
• Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. 2013. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 56(4):696–708.
   PubMed Web of Science ®Google Scholar
• Klen J, Dolzan V, Janez A. 2014. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. Eur J Clin Pharmacol. 70(4):421–428.
   PubMed Web of Science ®Google Scholar
• Li Q, Tang TT, Jiang F, Zhang R, Chen M, Yin J, Bao YQ, Cheng X, Hu C, Jia WP. 2017. Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes. Acta Pharmacol Sin. 38(1):80–89.
   PubMed Web of Science ®Google Scholar
• Liao W-L, Lee W-J, Chen C-C, Lu CH, Chen C-H, Chou Y-C, Lee I-T, Sheu W-H, Wu J-Y, Yang C-F, et al. 2017. Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes. Oncotarget. 8(11):18050–18058.
   PubMedGoogle Scholar
• Lin CH, Lee Y, Huang YY, Hsieh SH, Chen ZS, Tsai CN. 2015. Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes. J Diabetes Res. 2015:176949.
   PubMed Web of Science ®Google Scholar
• Mamza J, Mehta R, Donnelly R, Idris I. 2016. Determinants of glycemic response to add-on therapy with a dipeptidyl peptidase-4 inhibitor: a retrospective cohort study using a United Kingdom primary care database. Diabetes Technol Ther. 18(2):85–92.
   PubMed Web of Science ®Google Scholar
• Martin AM, Sun EW, Rogers GB, and Keating DJ. 2019. The influence of the gut microbiome on host metabolism through the regulation of gut hormone release. Front Physiol. 10:428.
   PubMed Web of Science ®Google Scholar
• Martono DP, Lub R, Lambers Heerspink HJ, Hak E, Wilffert B, Denig P. 2015. Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review. Diabet Med. 32(7):853–864.
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Nreu B, Andreozzi F, Sesti G, Mannucci E. 2017. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetol. 54(12):1101–1114.
   PubMed Web of Science ®Google Scholar
• [NICE] National Institute for Health and Care Excellence 2017. Algorithm for blood glucose lowering therapy in adults with type 2 diabetes. [accessed 2019 Aug 14] https://www.nice.org.uk/guidance/ng28
   Google Scholar
• Nikolac N, Simundic AM, Katalinic D, Topic E, Cipak A, Zjacic Rotkvic V. 2009. Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms. Arch Med Res. 40(5):387–392.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Meguro S, Sekioka R, Tanaka K, Saisho Y, Irie J, Tanaka M, Kawai T, Itoh H. 2015. A reduction of HbA1c after 3 months predicts 2-year responsiveness to sitagliptin treatment. Intern Med. 54(23):2981–2989.
   PubMed Web of Science ®Google Scholar
• Osada UN, Sunagawa H, Terauchi Y, Ueda S. 2016. A common susceptibility gene for type 2 diabetes is associated with drug response to a DPP-4 inhibitor: pharmacogenomic cohort in Okinawa Japan. PLoS One. 11(5):e0154821.
   PubMed Web of Science ®Google Scholar
• Park JE, Jeong GH, Lee IK, Yoon YR, Liu KH, Gu N, Shin KH. 2018. A pharmacometabolomic approach to predict response to metformin in early-phase type 2 diabetes mellitus patients. Molecules. 23(7):1579.
   Web of Science ®Google Scholar
• Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. 2014. Metformin pharmacogenomics: current status and future directions. Diabetes. 63(8):2590–2599.
   PubMed Web of Science ®Google Scholar
• Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI, Hattersley AT, Morris AD, Palmer CN. 2007. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes. 56(8):2178–2182.
   PubMed Web of Science ®Google Scholar
• Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, et al. 2006. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 355(5):467–477.
   PubMed Web of Science ®Google Scholar
• Phani NM, Vohra M, Adhikari P, Nagri SK, Shashikiran U, D'Souza SC, Kalluri PRR, Satyamoorthy K, Rai PS. 2017. Genetic variants identified from GWAS for predisposition to type 2 diabetes predict sulfonylurea drug response. Curr Mol Med. 17(8):580–586.
   PubMed Web of Science ®Google Scholar
• Ren Q, Han X, Tang Y, Zhang X, Zou X, Cai X, Zhang S, Zhang L, Li H, Ji L. 2014. Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. Diabetologia. 57(4):746–753.
   PubMed Web of Science ®Google Scholar
• Ren Q, Xiao D, Han X, Edwards SL, Wang H, Tang Y, Zhang S, Li X, Zhang X, Cai X, et al. 2016. Genetic and clinical predictive factors of sulfonylurea failure in patients with type 2 diabetes. Diabetes Technol Ther. 18(9):586–593.
   PubMed Web of Science ®Google Scholar
• Rottroff DM, Oki NO, Liang X, Yee SW, Stocker SL, Corum DG, Meiner M, Fiehn O, Motsinger-Reif AA, Giacoini KM, et al. 2016. Pharmacometabolomic assessment of metformin in non-diabetic, African Americans. Front Pharmacol. 7:135.
   PubMed Web of Science ®Google Scholar
• Sam WJ, Roza O, Hon YY, Alfaro RM, Calis KA, Reynolds JC, Yanovski JA. 2017. Effects of SLC22A1 polymorphisms on metformin-induced reductions in adiposity and metformin pharmacokinetics in obese children with insulin resistance. J Clin Pharmacol. 57(2):219–229.
   PubMed Web of Science ®Google Scholar
• Sato R, Watanabe H, Genma R, Takeuchi M, Maekawa M, Nakamura H. 2010. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics. 11(12):1743–1750.
   PubMed Web of Science ®Google Scholar
• Schafer SA, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B, Holst JJ, Dekker JM, t’Hart LM, Nijpels G, et al. 2007. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms [Research Support, Non-U.S. Gov't]. Diabetologia. 50(12):2443–2450.
   PubMed Web of Science ®Google Scholar
• Schroner Z, Dobrikova M, Klimcakova L, Javorsky M, Zidzik J, Kozarova M, Hudakova T, Tkacova R, Salagovic J, Tkac I. 2011a. Variation in KCNQ1 is associated with therapeutic response to sulphonylureas. Med Sci Monit. 17(7):CR392–396.
   PubMed Web of Science ®Google Scholar
• Schroner Z, Javorsky M, Tkacova R, Klimcakova L, Dobrikova M, Habalova V, Kozarova M, Zidzik J, Rudikova M, Tkac I. 2011b. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes Obes Metab. 13(1):89–91.
   PubMed Web of Science ®Google Scholar
• Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, Gnasso A, Grupillo M, Lauro R, Hribal ML, et al. 2006. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab. 91(6):2334–2339.
   PubMed Web of Science ®Google Scholar
• Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, Irace C, Lauro D, Gnasso A, Federici M, et al. 2004. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes [Research Support, Non-U.S. Gov't]. Diabetes Care. 27(6):1394–1398.
   PubMed Web of Science ®Google Scholar
• Shimajiri Y, Yamana A, Morita S, Furuta H, Furuta M, Sanke T. 2013. Kir6.2 E23K polymorphism is related to secondary failure of sulfonylureas in non-obese patients with type 2 diabetes. J Diabetes Investig. 4(5):445–449.
   PubMed Web of Science ®Google Scholar
• Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, et al. 2008. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 83(2):273–280.
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, et al. 2007. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 117(5):1422–1431.
   PubMed Web of Science ®Google Scholar
• Simioni N, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, Frontoni S, Genovese S, Ponzani P, Provenzano V, ReaL (NN2211-4118) Study Group, et al. 2018. Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting. Acta Diabetol. 55(6):557–568.
   PubMed Web of Science ®Google Scholar
• Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, Shin JG. 2008. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 84(5):559–562.
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Kaur V, Chamarthi B, Littleton KR, Chen L, Manning AK, Merino J, Thomas MK, Hudson M, Goldfine A, et al. 2018. TCF7L2 Genetic variation augments incretin resistance and influences response to a sulfonylurea and metformin: the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). Diabet Care. 41(3):554–561.
   PubMed Web of Science ®Google Scholar
• Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, Ramirez AH, Roden DM, Wilke RA, McCarty CA, et al. 2013. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 93(2):186–194.
   PubMed Web of Science ®Google Scholar
• Sun YV, Hu Y-J. 2016. Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases. Adv Genet. 93:147–190.
   PubMed Web of Science ®Google Scholar
• Surendiran A, Pradhan SC, Agrawal A, Subrahmanyam DK, Rajan S, Anichavezhi D, Adithan C. 2011. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol. 67(8):797–801.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Akiyama M, Ishigaki K, Kanai M, Hosoe J, Shojima N, Hozawa A, Kadota A, Kuriki K, Naito M, et al. 2019. Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population. Nat Genet. 51(3):379–386.
   PubMed Web of Science ®Google Scholar
• Tan K, Tesar C, Wilton R, Jedrzejczak RP, Joachimiak A. 2018. Interaction of antidiabetic α-glucosidase inhibitors and gut bacteria α-glucosidase. Protein Sci. 27(8):1498–1508.
   PubMed Web of Science ®Google Scholar
• Tkáč I, Javorský M, Klimčáková L, Židzik J, Gaľa I, Babjaková E, Schroner Z, Štolfová M, Hermanová H, Habalová V. 2015. A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes. Eur J Clin Pharmacol. 71(1):59–63.
   PubMed Web of Science ®Google Scholar
• Tkac I, Klimcakova L, Javorsky M, Fabianova M, Schroner Z, Hermanova H, Babjakova E, Tkacova R. 2013. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab. 15(2):189–191.
   PubMed Web of Science ®Google Scholar
• ‘t Hart LM, Fritsche A, Nijpels G, van Leeuwen N, Donnelly LA, Dekker JM, Alssema M, Fadista J, Carlotti F, Gjesing AP, et al. 2013. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes. 62(9):3275–3281.
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolic I, Koepsell H, Brockmoller J. 2009. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 86(3):299–306.
   PubMed Web of Science ®Google Scholar
• van Leeuwen N, Nijpels G, Becker ML, Deshmukh H, Zhou K, Stricker BHC, Uitterlinden AG, Hofman A, van 't Riet E, Palmer CNA, et al. 2012. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia. 55(7):1971–1977.
   PubMed Web of Science ®Google Scholar
• Wang ZJ, Yin OQ, Tomlinson B, Chow MS. 2008. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 18(7):637–645.
   PubMed Web of Science ®Google Scholar
• Wilson JR, Shuey MM, Brown NJ, Devin JK. 2017. Hypertension and type 2 diabetes are associated with decreased inhibition of dipeptidyl peptidase-4 by sitagliptin. J Endocr Soc. 1(9):1168–1178.
   PubMed Web of Science ®Google Scholar
• Woods A, Leiper JM, Carling D. 2012. The role of ATM in response to metformin treatment and activation of AMPK. Nat Genet. 44(4):360–361.
   PubMedGoogle Scholar
• Wright A, Burden AC, Paisey RB, Cull CA, Holman RR, U.K. Prospective Diabetes Study Group. 2002. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 25(2):330–336.
   PubMed Web of Science ®Google Scholar
• Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manneras-Holm L, Stahlman M, Olsson LM, Serino M, Planas-Felix M, et al. 2017. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 23(7):850–858.
   PubMed Web of Science ®Google Scholar
• Zeng W, Guo Y, Chen P, Liu Z, Chen D, Han C. 2016. CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients. J Diabetes Investig. 7(5):764–768.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu X, Kuang H, Yi R, Xing H. 2007. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Res Clin Pract. 77(1):58–61.
   PubMed Web of Science ®Google Scholar
• Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, et al. 2011. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics. 43(2):117–120.
   PubMed Web of Science ®Google Scholar
• Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Lang CC, et al. 2010. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther. 87(1):52–56.
   PubMed Web of Science ®Google Scholar
• Zhou K, Donnelly L, Yang J, Li M, Deshmukh H, Van Zuydam N, Ahlqvist E, Spencer CC, Groop L, Morris AD, et al. 2014. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol. 2(6):481–487.
   PubMed Web of Science ®Google Scholar
• Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Palmer CN, et al. 2009. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 58(6):1434–1439.
   PubMed Web of Science ®Google Scholar
• Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, Groves CJ, Coleman RL, van der Heijden AA, Beulens JW, et al. 2016. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet. 48(9):1055–1059.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Guo Y, Ye W, Wang Y, Li X, Tian Y, Liu Z, Li S, Yan J. 2014. RS11212617 is associated with metformin treatment response in type 2 diabetes in Shanghai local Chinese population. Int J Clin Pract. 68(12):1462–1466.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hu C, Zhao X, Luo P, Lu J, Li Q, Chen M, Yan D, Lu X, Kong H, et al. 2018. Serum metabolomics study of gliclazide-modified-release-treated type 2 diabetes mellitus patients using a gas chromatography-mass spectrometry method. J Proteome Res. 17(4):1575–1585.
   PubMed Web of Science ®Google Scholar
• Zimdahl H, Haupt A, Brendel M, Bour L, Machicao F, Salsali A, Broedl UC, Woerle HJ, Haring HU, Staiger H. 2017. Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes. Pharmacogenet Genomics. 27(4):135–142.
   PubMed Web of Science ®Google Scholar
• Zimdahl H, Ittrich C, Graefe-Mody U, Boehm BO, Mark M, Woerle HJ, Dugi KA. 2014. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia. 57(9):1869–1875.
   PubMed Web of Science ®Google Scholar